Announcements and Notices - [Closure of Books or Change of Book Closure Period]

RemeGen Co., Ltd. operates biotechnology businesses. The Company develops therapeutic antibody drugs such as antibody drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and double antibodies. RemeGen provides solutions autoimmune diseases, tumor diseases, and ophthalmic diseases.

Closure Of Register Of Members For 2025 First Extraordinary General Meeting

Announcements and Notices - [Change in Directors or of Important Executive Functions or Responsibilities]

Announcement On The Resignation Of
An Independent Non-Executive Director

Announcements and Notices - [Inside Information / Quarterly Results / Overseas Regulatory Announcement - Trading Update]

2024 Third Quarterly Report

Announcements and Notices - [Date of Board Meeting]

Date Of Board Meeting

Financial Statements/ESG Information - [Interim/Half-Year Report]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Remegen (9995 HK)

Closure Of Register Of Members For 2025 First Extraordinary General Meeting

Announcement On The Resignation Of An Independent Non-Executive Director

2024 Third Quarterly Report

Date Of Board Meeting

2024 Interim Report

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)